| AUROC (95% CI) | TN | FN | TP | FP | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | P |
---|---|---|---|---|---|---|---|---|---|---|
All patients (n = 102) | ||||||||||
SUV1 (≥ 2.2) | 0.74 (0.59–0.88) | 70 | 5 | 10 | 17 | 66.7% (38.4–88.2%) | 80.5% (70.6–88.2%) | 37.0% (25.2–50.7%) | 93.3% (87.2–96.7%) |  |
SUV2 (≥ 2.2) | 0.76 (0.62–0.90) | 69 | 4 | 11 | 18 | 73.3% (44.9–92.2%) | 79.3% (69.3–87.3%) | 37.9% (26.8–50.5%) | 94.4% (87.8–97.5%) | 0.58 |
SUV1 + RI (≥ 3%) | 0.75 (0.60–0.91) | 79 | 6 | 9 | 8 | 60.0% (32.3–83.7%) | 90.8% (82.7–96.0%) | 52.9% (34.1–71.0%) | 92.9% (87.6–96.1%) | 0.62 |
Equivocal (n = 24) | ||||||||||
SUV1 (≥ 2.2) | 0.67 (0.39–0.89) | 9 | 1 | 5 | 9 | 83.3% (35.9–99.6%) | 50.0% (26.0–74.0%) | 22.3% (13.8–34.0%) | 94.6% (73.3–99.1%) |  |
SUV2 (≥ 2.2) | 0.78 (0.56–0.94) | 10 | 0 | 6 | 8 | 100% (54.1–100%) | 55.6% (30.8–78.5%) | 27.9% (18.8–39.4%) | 100%(65.5–100%) | 0.29 |
SUV1 + RI (≥ 3%) | 0.72 (0.47–0.97) | 14 | 2 | 4 | 4 | 66.7% (22.3–95.7%) | 77.8% (52.4–96.6%) | 34.1% (15.5–59.2%) | 93.1% (81.0–97.7%) | 0.58 |
HPV-negative OPSCC (n = 21) | ||||||||||
SUV1 (≥ 2.2) | 0.82 (0.60–1) | 12 | 1 | 5 | 3 | 83.3% (35.9–99.6%) | 80.0% (51.9–95.7%) | 41.8% (19.7–67.8%) | 96.5% (82.1–99.4%) |  |
SUV2 (≥ 2.2) | 0.88 (0.69–1) | 14 | 1 | 5 | 1 | 83.3% (35.9–99.6%) | 93.3% (68.1–99.8%) | 68.3% (23.9–93.7%) | 97.0% (84.4–99.5%) | 0.14 |
SUV1 + RI (≥ 3%) | 0.88 (0.69–1) | 14 | 1 | 5 | 1 | 83.3% (35.9–99.6%) | 93.3% (68.1–99.8%) | 68.3% (23.9–93.7%) | 97.0% (84.4–99.5%) | 0.14 |
HPV-associated OPSCC (n = 32) | ||||||||||
SUV1 (≥ 2.2) | 0.56 (0.20–0.93) | 23 | 2 | 1 | 6 | 33.3% (0.8–90.6%) | 79.3% (60.3–92.0%) | 21.7% (4.6–61.6%) | 87.4% (75.2–94.0%) |  |
SUV2 (≥ 2.2) | 0.75 (0.42–1) | 24 | 1 | 2 | 5 | 66.7% (9.4–99.2%) | 82.8% (64.2–94.2%) | 40.0% (17.7–67.3%) | 93.5% (74.3–98.6%) | 0.29 |
SUV1 + RI (≥ 3%) | 0.47 (0.14–0.80) | 27 | 3 | 0 | 2 | 0.0% (0.0–70.8%) | 93.1% (77.2–99.2%) | 0.0%(0.0–80.2%) | 84.4% (83.0–85.6%) | 0.57 |